
Agreement - November 23, 2021
Vaccibody becomes Nykode and enters agreement worth 900 MUSD
The new name and identity signifies a new phase of growth for the company and the agreement with US-based Regeneron is worth up to 900 million USD. The multi-target license and collaboration agreement with Regeneron includes five distinct programs, three within cancer and two within infectious diseases. Each of these may include several vaccine candidates, […]

Collaboration - August 9, 2021
AstraZeneca and Regeneron collaborate
AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities. The companies will evenly split research and development costs and share equally in any future potential profits. “We are pleased to announce this important collaboration […]